The availability of safe and effective oral direct-acting antivirals (DAAs) has paved the path to eliminating hepatitis C (HCV) infection. Accordingly, the World Health Organisation (WHO) addressed a global target in 2016 for the elimination of HCV ...

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide. Essentially, persistent hepatitis B virus (HBV) infection is one of the most important risk factors for HCC1. Thus, targeted strategies to mitigate HBV ...

Hepatocellular carcinoma (HCC) is ranked as the sixth most common cancer worldwide and its incidence has been progressively increasing. HCC is also the third most common cause of cancer-related death, with a 5-year survival rate of just 3% 1 . Inter...

Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in children, with an estimated global prevalence of 5–7% in school-aged children. It is characterised by hyperactivity and impulsivity with ...

The POEMS syndrome is a rare plasma cell disorder involving pathological changes of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes. The diagnostic and therapeutic management of the disease is clinically challenging. Given ...

The 9 th Annual Scientific Meeting of the Hong Kong Society of Hepatobiliary and Pancreatic Surgery Liver cancer is one of the leading causes of cancer-related death globally. The prognosis of liver cancers is usually poor, and predicting life expec...

“The current progress of HCV elimination in Hong Kong is a bit left behind, yet latest strategies and policy have loosen access criteria for Direct-Acting Antiviral (DAA) therapies, making it possible for Hong Kong to catch up with other count...

Treatment on Antibiotic Resistance in Helicobacter Pylori Helicobacter pylori (H. pylori) is a bacterium that infects more than half of the worldwide population. H. pylori infection is the main cause of chronic gastritis and the etiological agent fo...

"The current progress of HCV elimination in Hong Kong is a bit left behind, yet latest strategies and policy have loosen access criteria for Direct-Acting Antiviral (DAA) therapies, making it possible for Hong Kong to catch up with other countr...

Current Efforts on HCV Elimination in Hong Kong “There is still a long way to go if Hong Kong were to achieve the WHO goal by 2030,” commented Dr. Mak. Indeed, a retrospective study by Hui et al (2018) involving 11,309 anti-HCV positive ...

Current Handling of HCV Treatment With the current approach of hepatitis C virus (HCV) treatment, Hong Kong has aligned itself with the World Health Organization (WHO) strategy to eliminate viral hepatitis as a major public health threat by 2030 1 ....

Pharmacological Advantages of TAF over TDF Both TDF and TAF are recommended as the first-line therapy for CHB management 5 . However, TAF is more stable than TDF in plasma and delivers the active metabolite to hepatocytes more efficiently, allowing ...